-
公开(公告)号：US11564968B2
公开(公告)日：2023-01-31
申请号：US17491837
申请日：2021-10-01
申请人： CAMURUS AB
摘要： The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
-
公开(公告)号：US20210308226A1
公开(公告)日：2021-10-07
申请号：US17350363
申请日：2021-06-17
申请人： CAMURUS AB
发明人： Fredrik Tiberg , Catalin Nistor , Markus Johnsson
摘要： The present invention relates to compositions forming a low viscosity mixture of: a)
20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b)
20-80 wt. % of at least one phosphatidyl choline (PC); c)
5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d)
up to 20 wt. % polar solvent e)
at least one peptide active agent; f)
optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.-
公开(公告)号：US20180250286A1
公开(公告)日：2018-09-06
申请号：US15866043
申请日：2018-01-09
申请人： Camurus AB
发明人： Fredrik Tiberg , Ian Harwigsson , Markus Johnsson
IPC分类号： A61K31/4748 , A61K31/485
CPC分类号： A61K31/4748 , A61K9/0024 , A61K31/485 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/34
摘要： A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
-
公开(公告)号：US09937164B2
公开(公告)日：2018-04-10
申请号：US14416421
申请日：2013-07-26
申请人： CAMURUS AB
发明人： Fredrik Tiberg , Ian Harwigsson , Markus Johnsson
IPC分类号： A61K31/4748 , A61K31/485
CPC分类号： A61K31/4748 , A61K31/485
摘要： A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
-
公开(公告)号：US20180015031A1
公开(公告)日：2018-01-18
申请号：US15520946
申请日：2015-10-27
申请人： CAMURUS AB
发明人： Fredrik TIBERG , Markus JOHNSSON , Ian HARWIGSSON
CPC分类号： A61K9/0019 , A61K9/0024 , A61K31/485 , A61K47/12 , A61K47/20 , A61K47/22 , A61K47/44
摘要： The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
-
公开(公告)号：US11672843B2
公开(公告)日：2023-06-13
申请号：US14401559
申请日：2013-05-24
申请人： CAMURUS AB
发明人： Catalin Nistor , Markus Johnsson , Fredrik Tiberg
IPC分类号： A61K38/12 , A61K38/08 , A61K9/00 , A61K38/31 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K38/04 , A61K47/10 , A61K47/14 , A61K47/24 , A61K31/4045 , A61K9/127 , C07K7/64 , A61K47/18
CPC分类号： A61K38/12 , A61K9/0019 , A61K9/0024 , A61K9/1274 , A61K31/4045 , A61K38/08 , A61K38/31 , A61K47/10 , A61K47/14 , A61K47/24 , C07K7/64 , A61K47/183
摘要： The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
-
公开(公告)号：US20220387445A1
公开(公告)日：2022-12-08
申请号：US17836120
申请日：2022-06-09
申请人： CAMURUS AB
IPC分类号： A61K31/5585 , A61P9/10 , A61P9/12 , A61K9/00 , A61K31/192 , A61K31/5575 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/24 , A61K45/06 , A61K47/14
摘要： The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di- or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
-
公开(公告)号：US11369617B2
公开(公告)日：2022-06-28
申请号：US16333448
申请日：2017-09-15
申请人： CAMURUS AB
IPC分类号： A61K31/5585 , A61P9/10 , A61P9/12 , A61K9/00 , A61K31/192 , A61K31/5575 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/24 , A61K45/06 , A61K47/14
摘要： The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
-
公开(公告)号：US20220168381A1
公开(公告)日：2022-06-02
申请号：US17491837
申请日：2021-10-01
申请人： CAMURUS AB
摘要： The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin receptor agonist; wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %. The invention further relates to methods of treatment comprising administration of such pre-formulations, to pre-filled administration devices and kits containing the formulations, to the use of an alkylammonium EDTA salt to reduce the decomposition of the lipid components and/or any active agent contained within the pre-formulation.
-
公开(公告)号：US20210308041A1
公开(公告)日：2021-10-07
申请号：US17234989
申请日：2021-04-20
申请人： CAMURUS AB
发明人： Fredrik TIBERG , Markus JOHNSSON , Ian HARWIGSSON
摘要： The present invention provides an injectable liquid formulation comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.02 秒)
